The PLK-1 inhibitors market is experiencing robust growth driven by increasing investments in cancer research and the expanding pipeline of novel therapeutic agents. The rising prevalence of cancer and demand for targeted therapies are fueling market expansion. Additionally, advancements in clinical trials and rising collaborations between pharmaceutical companies are further propelling the market forward.
LAS VEGAS, Oct. 1, 2024 /PRNewswire/ -- DelveInsight's PLK-1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging PLK-1 inhibitors, market share of individual therapies, and current and forecasted PLK-1 inhibitors market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the PLK-1 Inhibitors Market Report
- As per DelveInsight's analysis, the total market size of PLK-1 inhibitors in the 7MM is expected to surge significantly by 2034.
- Leading PLK-1 inhibitor companies such as Cardiff Oncology, Notable Labs, Cyclacel Pharmaceuticals, and others are developing novel PLK-1 inhibitors that can be available in the PLK-1 inhibitors market in the coming years.
- Some of the key PLK-1 inhibitors in the pipeline include Onvansertib, Volasertib (NBL-001, BI 6727), Plogosertib (CYC140), and others.
- In 2019, Oncoheroes Biosciences and Boehringer Ingelheim signed an exclusive licensing agreement for volasertib. Moreover, global development and commercialization rights to volasertib in adult disease indications were acquired by Notable from Oncoheroes Biosciences in 2021.
Discover which therapies are expected to grab the PLK-1 inhibitors market share @ PLK-1 Inhibitors Market Report
PLK-1 Inhibitors Market Dynamics
The PLK-1 inhibitors market is a rapidly evolving sector within the oncology pharmaceutical landscape. One of the primary drivers of the PLK-1 inhibitors market is the increasing prevalence of cancer and the demand for more effective and targeted therapies. With the global cancer burden continuing to rise, there is a growing need for drugs that can specifically target the molecular mechanisms involved in cancer cell proliferation. PLK-1 inhibitors are positioned as promising candidates due to their potential to interfere with critical processes in tumor growth. This has led to substantial investment in research and clinical trials aimed at validating their efficacy and safety.
The market dynamics are also influenced by regulatory developments and clinical trial outcomes. As PLK-1 inhibitors advance through clinical trials, their success in demonstrating clinical benefits and manageable side effects will play a crucial role in shaping market opportunities. Regulatory approvals and endorsements from major health authorities can significantly impact market entry and adoption rates. Additionally, the availability of robust clinical trial data will be a key factor in attracting investment and partnerships, further driving market growth.
However, the market is not without its challenges. The development of PLK-1 inhibitors faces several hurdles, including the need for precise patient stratification and overcoming potential resistance mechanisms. Additionally, the high cost of research and development, coupled with the need for comprehensive clinical testing, can pose financial risks for companies. Competitive pressures from other emerging cancer therapies and potential market saturation may also impact the profitability and strategic positioning of PLK-1 inhibitors.
PLK-1 Inhibitors Treatment Market
PLK-1 inhibitors are drugs designed to target and block the activity of polo-like kinase 1 (PLK-1), a protein crucial for cell division and growth. These inhibitors are being investigated primarily in cancer treatments because they can potentially disrupt the growth and survival of tumor cells.
In the context of cancer therapy, PLK-1 inhibitors have shown potential in early research and initial clinical trials. By inhibiting PLK-1, these drugs interfere with the cell cycle, leading to halted cell division and triggering cell death in cancerous cells.
Research is ongoing to evaluate the effectiveness of PLK-1 inhibitors across various cancer types, including both solid tumors and blood cancers. Efforts are focused on understanding how these inhibitors work, finding biomarkers to help select appropriate patients, and determining how best to use them, whether alone or alongside other cancer treatments.
The development of PLK-1 inhibitors is an exciting advancement in cancer research, with the potential to provide new treatment options. However, more clinical trials are needed to fully assess their safety, effectiveness, and optimal application for different cancers and patient groups.
Learn more about the FDA-approved PLK-1 inhibitors @ PLK-1 Inhibitors Drugs
Key Emerging PLK-1 Inhibitors and Companies
Several PLK-1 inhibitors, such as BI2536, BI6727 (volasertib), GSK461364, and NMS-1286937 (onvansertib), have been tested in clinical trials. These inhibitors are ATP-competitive and have similar mechanisms of action. Specifically, GSK461364, BI2536, and BI6727 interact with the Cys133 residue, while NMS-1286937 interacts with both Glu131 and Cys133.
While PLK1 inhibitors like BI2536, BI6727, and NMS-1286937 generally have good tolerability and pharmacokinetic profiles, their clinical success is limited due to partial responses, particularly in advanced cancer stages. As a result, there is a growing interest in combination therapies that target multiple pathways for better cancer management.
Despite the promise of PLK1 inhibition-based monotherapy, it hasn't achieved complete responses for all patients. To overcome this, researchers are now exploring combinations of PLK1 inhibitors with other treatments. This approach is driven by the understanding that tumors are plastic and heterogeneous. By targeting multiple pathways simultaneously, combination therapy aims to address the diverse genetic backgrounds of cancer cells, potentially leading to more effective and synergistic anticancer effects and reducing the likelihood of drug resistance.
Volasertib showed notable clinical responses in a subset of patients during both phase 2 and phase 3 randomized trials, with response rates between 25% and 27%. However, another group of patients did not benefit from volasertib and experienced negative side effects. While the phase 2 trial achieved statistical significance, the phase 3 trial did not due to the lack of a predictive biomarker to identify patients likely to respond. Notable Labs plans to use its predictive precision medicine platform (PPMP) to better select patients who might benefit from volasertib and initiate a Phase II trial.
Key players in the development of PLK-1 inhibitors for various conditions, including metastatic colorectal cancer, acute myeloid leukemia, myelodysplastic syndromes, triple-negative breast cancer, and small cell lung cancer, include Notable Labs and Cardiff Oncology, among others.
The anticipated launch of these emerging therapies are poised to transform the PLK-1 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the PLK-1 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about PLK-1 inhibitors clinical trials, visit @ PLK-1 Inhibitors Treatment Drugs
PLK-1 Inhibitors Overview
PLK-1 inhibitors are a class of targeted cancer therapeutics designed to impede the activity of Polo-like kinase 1 (PLK-1), a protein critical for cell division and mitosis. PLK-1 is overexpressed in many cancers, where it contributes to uncontrolled cell proliferation by regulating key processes such as spindle formation, chromosome segregation, and cytokinesis. By inhibiting PLK-1, these drugs aim to disrupt the cancer cells' ability to complete mitosis properly, leading to cell cycle arrest and eventual apoptosis. This makes PLK-1 inhibitors a promising approach in the treatment of various malignancies, including breast, lung, and prostate cancers.
Research into PLK-1 inhibitors has led to the development of several compounds currently in clinical trials. These inhibitors can be categorized into different classes, including ATP-competitive and allosteric inhibitors. ATP-competitive inhibitors bind to the active site of PLK-1, blocking its kinase activity, while allosteric inhibitors bind to a different site on the enzyme, inducing a conformational change that impedes its function. Despite their potential, the clinical efficacy of PLK-1 inhibitors can be limited by factors such as drug resistance, toxicity, and the complexity of cancer biology. Ongoing studies are focused on optimizing these inhibitors and combining them with other therapies to enhance their effectiveness and reduce side effects.
PLK-1 Inhibitors Epidemiology Segmentation
The PLK-1 inhibitors market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
- Total Prevalent Cases in Selected Indications for PLK-1 Inhibitors
- Total Eligible Patient Pool for PLK-1 Inhibitors in Selected Indications
- Total Treated Cases in Selected Indications for PLK-1 Inhibitors
PLK-1 Inhibitors Report Metrics | Details |
Study Period | 2020-2034 |
PLK-1 Inhibitors Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key PLK-1 Inhibitors Companies | Cardiff Oncology, Notable Labs, Cyclacel Pharmaceuticals, and others |
Key PLK-1 Inhibitors | Onvansertib, Volasertib (NBL-001, BI 6727)), Plogosertib (CYC140), and others |
Scope of the PLK-1 Inhibitors Market Report
- PLK-1 Inhibitors Therapeutic Assessment: PLK-1 Inhibitors current marketed and emerging therapies
- PLK-1 Inhibitors Market Dynamics: Conjoint Analysis of Emerging PLK-1 Inhibitors Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, PLK-1 Inhibitors Market Access and Reimbursement
Discover more about PLK-1 inhibitors in development @ PLK-1 Inhibitors Clinical Trials
Table of Contents
1. | Key Insights |
2. | Report Introduction |
3. | Executive Summary of PLK-1 Inhibitors |
4. | Key Events |
5. | Market Forecast Methodology |
6. | PLK-1 Inhibitors Market Overview at a Glance in the 7MM |
6.1. | Market Share (%) Distribution by Indication in 2020 |
6.2. | Market Share (%) Distribution by Indication in 2034 |
7. | PLK-1 Inhibitors: Background and Overview |
7.1. | Introduction |
7.2. | Evolution of PLK-1 Inhibitors |
7.3. | Treatment |
8. | Target Patient Pool |
8.1. | Key Findings |
8.2. | Assumptions and Rationale: 7MM |
8.3. | Epidemiology Scenario in the 7MM |
8.3.1. | Total Prevalent Cases in Selected Indications for PLK-1 Inhibitors in the 7MM |
8.3.2. | Total Eligible Patient Pool for PLK-1 Inhibitors in Selected Indications in the 7MM |
8.3.3. | Total Treated Cases in Selected Indications for PLK-1 Inhibitors in the 7MM |
8.4. | Epidemiology Scenario in the US |
8.4.1. | Total Prevalent Cases in Selected Indications for PLK-1 Inhibitors in the US |
8.4.2. | Total Eligible Patient Pool for PLK-1 Inhibitors in Selected Indications in the US |
8.4.3. | Total Treated Cases in Selected Indications for PLK-1 Inhibitors in the US |
8.5. | Epidemiology Scenario in EU4 and the UK |
8.5.1. | Total Prevalent Cases in Selected Indications for PLK-1 Inhibitors in EU4 and the UK |
8.5.2. | Total Eligible Patient Pool for PLK-1 Inhibitors in Selected Indications in EU4 and the UK |
8.5.3. | Total Treated Cases in Selected Indications for PLK-1 Inhibitors in EU4 and the UK |
8.6. | Epidemiology Scenario in Japan |
8.6.1. | Total Prevalent Cases in Selected Indications for PLK-1 Inhibitors in Japan |
8.6.2. | Total Eligible Patient Pool for PLK-1 Inhibitors in Selected Indications in Japan |
8.6.3. | Total Treated Cases in Selected Indications for PLK-1 Inhibitors in Japan |
9. | Emerging Therapies |
9.1. | Key Competitors |
9.2. | Onvansertib: Cardiff Oncology |
9.2.1. | Product Description |
9.2.2. | Other developmental activities |
9.2.3. | Clinical development |
9.2.4. | Safety and efficacy |
9.3. | Volasertib: Notable Labs |
9.3.1. | Product Description |
9.3.2. | Other developmental activities |
9.3.3. | Clinical development |
9.3.4. | Safety and efficacy |
List to be continued in the report | |
10. | PLK-1 Inhibitor: Seven Major Market Analysis |
10.1. | Key Findings |
10.2. | Market Outlook |
10.3. | Key Market Forecast Assumptions |
10.4. | Total Market Size of PLK-1 inhibitors in the 7MM |
10.5. | Market Size of PLK-1 Inhibitors by Indication in the7MM |
10.6. | The United States Market Size |
10.6.1. | Total Market Size of PLK-1 Inhibitors in the United States |
10.6.2. | Market Size of PLK-1 Inhibitors by Indication in the United States |
10.6.3. | Market Size of PLK-1 Inhibitors by Therapies in the United States |
10.7. | EU4 and the UK Market Size |
10.7.1. | Total Market Size of PLK-1 Inhibitors in EU4 and the UK |
10.7.2. | Market Size of PLK-1 Inhibitors by Indication in EU4 and the UK |
10.7.3. | Market Size of PLK-1 Inhibitors by Therapies in EU4 and the UK |
10.8. | Japan Market Size |
10.8.1. | Total Market Size of PLK-1 Inhibitors in Japan |
10.8.2. | Market Size of PLK-1 Inhibitors by Indication in Japan |
10.8.3. | Market Size of PLK-1 Inhibitors by Therapies in Japan |
11. | Market Access and Reimbursement |
12. | SWOT Analysis |
13. | KOL Views |
14. | Unmet Needs |
15. | Appendix |
15.1. | Bibliography |
15.2. | Report Methodology |
16. | DelveInsight Capabilities |
17. | Disclaimer |
18. | About DelveInsight |
Related Reports
Metastatic Colorectal Cancer Pipeline
Metastatic Colorectal Cancer Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic colorectal Cancer companies, including Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, among others.
Metastatic Colorectal Cancer Market
Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, AB Science, Daiichi Sankyo, Astrazeneca, Merck, Eisai, Mirati Therapeutics, Cardiff Oncology, among others.
Acute Myeloid Leukemia Market
Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including CicloMed LLC, Jazz Pharmaceuticals, Minneamrita Therapeutics LLC, Syndax Pharmaceuticals, Astex Pharmaceuticals, Inc., Karyopharm Therapeutics Inc, Sanofi, Polaris Group, Bio-Path Holdings, Inc., Chordia Therapeutics, Inc., Theradex, BioTheryX, Inc., Precigen, Inc, Eli Lilly and Company, Bayer, Takeda, Meryx, Inc., 2seventy bio, JW Pharmaceutical, Telios Pharma, Inc., Kartos Therapeutics, Inc., Celyad Oncology SA, Merck Sharp & Dohme LLC, Celgene, AbbVie, Genentech, Wugen, Inc., Arcellx, Inc, NextCure, Inc., Bellicum Pharmaceuticals, ImmunoGen, Inc., Astellas Pharma Inc, Aptose Biosciences Inc, Ascentage Pharma Group Inc., BioSight Ltd., GlycoMimetics Incorporated, Gilead Sciences, Chimerix, Daiichi Sankyo, Ryvu Therapeutics SA, Syros Pharmaceuticals, PrECOG, LLC, Cleave Therapeutics, Inc., Kronos Bio, Cullinan Oncology, LLC, Actinium Pharmaceuticals, Amgen, In8bio Inc, Sellas Life Sciences Group, Kura Oncology, Inc., Arog Pharmaceuticals, Inc., Novo Nordisk A/S, Marker Therapeutics, Inc., Shattuck Labs, Inc., Oncoceutics, Inc., among others.
Acute Myeloid Leukemia Pipeline
Acute Myeloid Leukemia Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute myeloid leukemia companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/plk-1-inhibitors-market-to-register-immense-growth-by-2034--delveinsight-302263542.html
